← Leaderboards
Wuyuan Lu
University Of Md Biotechnology Institute
$9,101,920
Attributed
$9,101,920
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$9,101,920 · 9
By mechanism
R01$5,771,172 · 4
R21$1,668,874 · 4
P01$1,661,874 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsBaseInhibitor/AntagonistIn VivoInfectionDesignAmino AcidsBinding (Molecular Function)KillingsCellsPlayProgramsResearch PersonnelDefensinsMolecularCessation Of LifeCell MembraneHiv-1PreventDrug DevelopmentIn VitroPeptidesEnzymesSmall Molecule
Grant awards (30)
Core B-Specimen and Reagent Core$670,497
P01 · FY2019 · AI · contact PI
Core B-Specimen and Reagent Core$358,562
P01 · FY2018 · AI · contact PI
Anticancer peptide therapeutics$353,419
R01 · FY2018 · CA · contact PI
Core B-Specimen and Reagent Core$389,369
P01 · FY2017 · AI · contact PI
Anticancer peptide therapeutics$353,419
R01 · FY2017 · CA · contact PI
Core B-Specimen and Reagent Core$243,446
P01 · FY2016 · AI · contact PI
D-peptide activators of p53 as anticancer therapeutics$166,931
R21 · FY2015 · CA · contact PI
High-throughput screening for HIV assembly and maturation inhibitors$291,650
R01 · FY2014 · GM · contact PI
D-peptide activators of p53 as anticancer therapeutics$200,318
R21 · FY2014 · CA · contact PI
High-throughput screening for HIV assembly and maturation inhibitors$281,442
R01 · FY2013 · GM · contact PI
High-throughput screening for HIV assembly and maturation inhibitors$291,650
R01 · FY2012 · GM · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$360,555
R01 · FY2011 · AI · contact PI
D-peptide inhibitors of HIV assembly and maturation$185,625
R21 · FY2011 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$364,197
R01 · FY2010 · AI · contact PI
D-peptide inhibitors of HIV assembly and maturation$225,000
R21 · FY2010 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$160,137
R01 · FY2010 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$504,953
R01 · FY2009 · AI · contact PI
Molecular Basis of Human Neutrophil a-Defensin Function$348,812
R01 · FY2009 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$367,875
R01 · FY2008 · AI · contact PI
Molecular Basis of Human Neutrophil alpha-Defensin Function$348,812
R01 · FY2008 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$371,250
R01 · FY2007 · AI · contact PI
Inhibition of Anthrax Lethal Factor by alpha-defensins$284,470
R01 · FY2007 · AI · contact PI
Molecular Basis of Human Neutrophil alpha-Defensin Function$274,277
R01 · FY2007 · AI · contact PI
Molecular Basis of Human Neutrophil alpha-Defensin Function$80,478
R01 · FY2007 · AI · contact PI
Molecular Basis of Human Neutrophil a-Defensin Function$362,526
R01 · FY2006 · AI · contact PI
Molecular Basis-Human Neutrophil alpha-Defensin Function$371,250
R01 · FY2005 · AI
Covalently Tethered Chemokines and HIV-1 Inhibition$222,750
R21 · FY2005 · AI
Functional Roles of S-S Bonding in Human Beta-Defensin 3$222,750
R21 · FY2004 · AI
Covalently Tethered Chemokines and HIV-1 Inhibition$222,750
R21 · FY2004 · AI
Functional Roles of S-S Bonding in Human Beta-Defensin 3$222,750
R21 · FY2003 · AI